{ }
001122334455554433221100
001122334455554433221100

ubs maintains buy rating for novo nordisk with target price of 750 kroner

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish kroner, driven by positive trends in weight loss drug prescriptions, particularly for GLP-1 appetite suppressants. Analyst Jo Walton noted that Eli Lilly's Zepbound is currently leading the market.

ubs maintains buy rating for novo nordisk with target price of 750 kroner

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish kroner, driven by positive trends in weight loss drugs, particularly GLP-1 appetite suppressants. Analyst Jo Walton noted that while all appetite suppressants are experiencing growth, Eli Lilly's Zepbound is leading the market.

ubs predicts over 50 percent recovery for novo nordisk shares

Novo Nordisk's shares have dropped over 20% this year, primarily due to disappointing results for its weight loss drug CagriSema and concerns about Wegovy's market performance against Eli Lilly's Zepbound. Despite this, UBS maintains a "buy" rating with a target price of 750 DKK, suggesting a potential 56% upside. Wall Street remains divided, with half of analysts recommending a buy and the other half advising to hold, but no sell ratings are present.

ubs maintains buy rating for novo nordisk with target price of 750 crowns

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns, influenced by current trends in weight loss drugs, particularly GLP-1. Analyst Jo Walton noted growth for Eli Lilly's Zepbound, while other competitors are seeing declines.

goldman sachs downgrades super micro computer amid ai market challenges

Goldman Sachs has downgraded Super Micro Computer (SMCI) to "sell," citing risks in the AI server market, increased competition, and low profit margins, with a new price target of $32. Meanwhile, AI startup Fyxer raised $10 million, and major tech firms like Tesla and AMD saw significant stock gains. Apple faces a 21% drop in iPhone shipments in China, while Microsoft and Salesforce are noted for their resilience amid potential software spending slowdowns.

UBS maintains buy rating and price target for Eli Lilly

UBS analyst Trung Huynh has reaffirmed a Buy rating on Eli Lilly (NYSE: LLY) with a price target of $1,100. The positive outlook reflects confidence in the company's performance and potential growth in the market.

hims and hers stock declines after bank of america raises price target

Hims & Hers Health stock fell 7.4% after Bank of America raised its price target by only $1 to $22, which is $10 below its current value. The bank reiterated its "underperform" rating, citing concerns over slowing growth due to the FDA's actions affecting GLP-1 product sales. With the stock trading at 65 times trailing earnings, analysts question its investment worthiness at this price.

stocks rise on inflation data despite losses from eli lilly and big tech

U.S. stocks mostly rose following positive inflation data, with the S&P 500 up 0.1% and the Dow Jones gaining 221 points. However, Eli Lilly's 6.6% drop and declines in several Big Tech stocks limited gains. Treasury yields stabilized after the inflation report, while H&E Equipment Services surged over 100% due to a buyout announcement.

stocks rise on wall street after positive inflation report

U.S. stocks rose slightly following positive wholesale inflation data, with the S&P 500 up 0.1% and the Dow Jones gaining 134 points. However, declines in major companies like Eli Lilly and Nvidia limited gains. H&E Equipment Services surged over 100% after a buyout announcement, while Signet Jewelers fell 21.5% due to disappointing holiday sales.

protests mark conclusion of j p morgan healthcare conference day two

The J.P. Morgan Healthcare Conference's second day featured presentations from GSK, Novartis, Sanofi, and Eli Lilly, following a day of significant deal announcements and financial overviews from major biopharma companies. As the first day concluded, attendees faced protests accusing the industry of prioritizing profits over lives, amid heightened police presence due to recent events, including the killing of UnitedHealthcare CEO Brian Thompson. Despite the protests, conference participants remained largely unaffected.

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.